Important Information for Investors: Viatris Securities Class Action Lawsuit
On April 10, 2025, Kahn Swick & Foti, LLC (“KSF”) and its partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notified the investing public that they have until June 3, 2025, to file lead plaintiff applications in a securities class action lawsuit against Viatris Inc. (the “Company” or “Viatris”). The lawsuit alleges that Viatris and certain of its executives violated federal securities laws by making false and misleading statements to the investing public during the period from August 8, 2024, to February 26, 2025, inclusive (the “Class Period”).
Background on Viatris
Viatris is a global healthcare company that provides branded and generic medicines to patients worldwide. The Company was formed through the merger of Mylan N.V. and Pfizer Inc.’s Upjohn business in October 2020.
Alleged Misstatements and Omissions
According to the complaint, Viatris and certain of its executives made false and misleading statements regarding the Company’s financial condition, business prospects, and compliance with regulatory requirements. Specifically, the complaint alleges that:
- The Company failed to disclose that it was experiencing significant supply chain disruptions, which would negatively impact its financial results;
- The Company inaccurately reported its financial results for the third quarter of 2024, including misstating its revenue and earnings per share;
- The Company failed to disclose that it was under investigation by the Securities and Exchange Commission (“SEC”) and the U.S. Department of Justice for potential violations of the Foreign Corrupt Practices Act;
Impact on Individual Investors
If you purchased or acquired Viatris securities during the Class Period and suffered a loss, you may be entitled to recover your loss. To learn more about the class action lawsuit and how to file a lead plaintiff application, you can contact KSF at 1-877-515-1850 or via email at [email protected].
Impact on the World
The securities class action lawsuit against Viatris is significant because it highlights the importance of transparency and accuracy in corporate reporting. Misrepresentations and omissions can have far-reaching consequences, affecting not only individual investors but also the broader financial markets and the economy as a whole. It is essential that companies provide accurate and timely information to their investors to ensure a level playing field and maintain confidence in the capital markets.
Conclusion
Investors who purchased or acquired Viatris securities during the Class Period and suffered a loss should consider their legal options. The securities class action lawsuit against Viatris underscores the importance of transparency and accuracy in corporate reporting and serves as a reminder to investors to carefully monitor their investments and seek professional advice when necessary.
For more information about this class action lawsuit and your potential recovery, contact KSF at 1-877-515-1850 or via email at [email protected].
About Kahn Swick & Foti, LLC: KSF is a law firm focused on securities class actions, derivative actions, and complex corporate litigation. The firm has significant experience in representing investors and recovering losses on their behalf. For more information about KSF, please visit www.ksfcounsel.com.
This press release may be considered attorney advertising in some jurisdictions under the applicable law and ethical rules.
Contact:
Kahn Swick & Foti, LLC
1-877-515-1850
[email protected]
1100 Poydras St., Suite 3200
New Orleans, LA 70163
1001 Avenue of the Americas, Suite 425
New York, NY 10018
Source: Kahn Swick & Foti, LLC
